Cite
HARVARD Citation
Moehler, M. et al. (2016). Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program. BMC cancer. 16 (1), pp. 1-13. [Online].